Oxandrolone, an anabolic steroid, is sometimes used in Turner syndrome (TS) to augment growth, particularly when combined with growth hormone (GH) therapy. Its impact on breast development is nuanced and primarily indirect:
1.Estrogen Dependency: Breast development in TS is driven by estrogen replacement therapy (ERT), typically initiated later to maximize height potential. Delayed ERT (not oxandrolone itself) is the primary reason for postponed breast development.
2.Androgenic Effects: While oxandrolone has mild androgenic properties, studies suggest it does not significantly impair breast development when ERT is adequately administered. Concerns about androgen interference are theoretical and not strongly supported by clinical evidence.
3.Clinical Evidence: Research indicates that oxandrolone improves adult height in TS without major adverse effects on puberty progression. Breast development proceeds normally once ERT begins, provided dosing and timing are appropriate.
4.Guidelines: Expert protocols recommend careful coordination of oxandrolone and ERT. Oxandrolone is generally considered safe for growth promotion without directly hindering breast development when managed alongside timely estrogen replacement.
5.Conclusion: Oxandrolone does not directly slow breast development in TS. Delayed breast development is more likely due to deferred ERT to optimize growth. Under medical supervision, oxandrolone can be used effectively with minimal impact on puberty outcomes.






